The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Covalent-103: A phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL).
 
Marcello Rotta
No Relationships to Disclose
 
Yasmin Abaza
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Celgene; Geron; Kite/Gilead; Pfizer; Rigel; SERVIER
Research Funding - Abbvie (Inst); ALX Oncology (Inst); Biomea Fusion (Inst); Biosight (Inst); Curis (Inst); Novartis (Inst)
 
Hetty E Carraway
Honoraria - BMSi; Jazz Pharmaceuticals; Novartis
Consulting or Advisory Role - BMS; Daiichi Sankyo/Lilly
Speakers' Bureau - Agios; BMSi; Jazz Pharmaceuticals
Research Funding - Celgene
Travel, Accommodations, Expenses - Jazz Pharmaceuticals; Novartis
Other Relationship - Syndax
 
Bradley W. Christensen
Honoraria - SOBI
 
Mitul Gandhi
Honoraria - GlaxoSmithKline; Janssen Oncology; Janssen Oncology (Inst); Karyopharm Therapeutics; Sanofi; TG Therapeutics
 
Paul B. Koller
Honoraria - Novartis; Takeda
Consulting or Advisory Role - Ascentage Pharma; Daiichi Sankyo/Lilly; Novartis; Takeda; Treadwell Therapeutics
Speakers' Bureau - Novartis; Takeda
 
Ayman H. Qasrawi
Honoraria - Sermo
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Autolus Therapeutics; Bristol-Myers Squibb/Celgene; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical; Rigel
Speakers' Bureau - Abbvie; Agios; Amgen; Astellas Pharma; Blueprint Medicines; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Rigel; Sanofi; Seattle Genetics/Astellas; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Aptevo Therapeutics; Arog; Astellas Pharma; AVM Biotechnology; Bio-Path Holdings; Biomea Fusion; Biosight; Bristol-Myers Squibb/Celgene; Celator; Cellectis; Celularity; Cogent Biosciences; Constellation Pharmaceuticals; Cullinan Oncology; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; Fate therapuetics; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; glycomimetics; Immune-Onc Therapeutics; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Kronos Bio; Kura Oncology; Loxo; Marker Therapeutics; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Syros Pharmaceuticals; Syros Pharmaceuticals; Takeda; Tolero Pharmaceuticals; Trovagene
 
Catherine Choy Smith
Consulting or Advisory Role - Abbvie/Genentech; Astellas Pharma
Research Funding - Abbvie; Celgene/Bristol-Myers Squibb (Inst); Erasc; Fujifilm (Inst); Revolution Medicines
 
Uzma Ahmed
Employment - Biomea Fusion
Stock and Other Ownership Interests - Biomea Fusion
 
Alexandru Cacovean
Employment - Biomea Fusion
Stock and Other Ownership Interests - Biomea Fusion
 
Nicole Kowalczyk
Employment - Biomea Fusion
Stock and Other Ownership Interests - Biomea Fusion
 
Stephan W. Morris
Employment - Biomea Fusion
Leadership - Biomea Fusion
Stock and Other Ownership Interests - Biomea Fusion
 
Mona Vimal
Employment - Biomea Fusion
Stock and Other Ownership Interests - Biomea Fusion
 
Sauji Yachamaneni
Employment - Biomea Fusion
Stock and Other Ownership Interests - Biomea Fusion
 
Thomas Butler
Employment - Biomea Fusion
Leadership - Biomea Fusion
Stock and Other Ownership Interests - Biomea Fusion
 
Eunice S. Wang
Consulting or Advisory Role - Abbvie; Celgene/Bristol-Myers Squibb; CTI BioPharma Corp; Daiichi Sankyo/UCB Japan; Gilead Sciences; GlaxoSmithKline; Immunogen; Janssen; Kite/Gilead; Kura Oncology; Novartis; Nuprobe; Qiagen; Rigel; Schrodinger; Sellas Life Sciences; Sumitomo Pharma Oncology; Syndax
Speakers' Bureau - Astellas Pharma; DAVA Pharmaceuticals; Pfizer
Other Relationship - Abbvie/Genentech; Gilead Sciences; Gilead Sciences
 
Farhad Ravandi-Kashani
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - Amgen; Astellas Pharma (Inst); Astex Pharmaceuticals; Biomea Fusion; Bristol-Myers Squibb; Cellerant; Macrogenics; Prelude Therapeutics; Selvita; Syros Pharmaceuticals; Taiho Oncology; Xencor